Crescendo Bioscience's Vectra DA predicts radiographic progression in patients with early RA

May 16, 2014

Crescendo Bioscience, a subsidiary of Myriad Genetics, Inc., has announced the online publication of a new study in the journal Annals of the Rheumatic Diseases supporting the efficacy of Crescendo's Vectra DA blood test. The study is a retrospective analysis of data from the Swedish Farmacotherapy (SWEFOT) clinical trial and shows that Vectra DA is a strong predictor of radiographically visible damage to joints, known as disease progression, in patients newly diagnosed with rheumatoid arthritis (RA). A multi-biomarker blood test validated to assess disease activity in patients with rheumatoid arthritis, Vectra DA integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of one to 100, to aid physicians in making more informed treatment decisions.

This study evaluated the Vectra DA test score as a predictor of one-year radiographic progression in 235 patients in SWEFOT. All patients had early rheumatoid arthritis and had not been previously treated with a disease-modifying anti-rheumatic drug. The results showed that the Vectra DA score at baseline was an independent predictor of radiographic progression over one year of DMARD treatment. Among the 201 patients with a high Vectra DA score at baseline, 21% had radiographic progression at one year.

The findings underscore the clinical value of Vectra DA for predicting disease progression in newly diagnosed patients with RA and its potential to help doctors manage patients based on their risk of disease progression. Importantly, these findings build on earlier results from the Leiden Early Arthritis Cohort study published in Rheumatology, which showed that patients with a high Vectra DA score were at a six-fold higher risk of disease progression than those with a low Vectra DA score. Read about the Vectra DA.

Read more